MREO
Mereo BioPharma Group plc (MREO) Risks & Opportunities Analysis (2026)
Overall Score
Balance Sheet Liquidity
Strong liquidity with a current ratio of 5.88 and cash ratio of 5.31.
Very low leverage, with debt-to-equity at 0.04 and debt-to-assets at 0.03.
Net current asset value remains positive at $27.3M, supporting downside protection.
Profitability Cash Flow
Operating performance remains deeply negative, with ROA at -0.81 and ROIC at -1.13.
Cash generation is still negative, with free cash flow per share at -0.16 and operating cash flow per share at -0.16.
Interest coverage remains extremely weak at -393.7, reflecting ongoing losses.
Valuation Downside Protection
The company still screens as asset-backed, with tangible book value per share at 0.18 and book value per share at 0.18.
Price-to-book is 1.50, which is not expensive for a cash-rich balance sheet.
Negative earnings and cash flow metrics limit the usefulness of earnings-based valuation multiples.
Operational Business Risk
The business remains unprofitable, with zero margins across gross, operating, and net profit lines in the latest data.
A very long cash conversion cycle of -456.3 days is distorted by unusually high payables, which can be a working-capital risk if it normalizes.
No recent news was provided, so there is no new catalyst to reduce execution or business-model risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

